Author | Lightnews

Reposted by Teja Kulkarni

Kerri Johannson MD MPH @kerrijohannson.bsky.social · 21d

The Impact of Pulmonary Fibrosis on Sex and Sexual Function - A Multinational Mixed Methods Study

Just out in ERJ and led by Dr. Na'ama Avitzur
A 🧵👇
(key take-away 👉 sex matters to patients with PF and their disease impacts this)

#OpenAccess #CurePF #CureIPF
publications.ersnet.org/content/erj/...

1 4 14

Teja Kulkarni @tkulkarni.bsky.social · 25d

The approval of Nerandomilast marks a pivotal step forward in IPF care. For patients living with IPF, this offers long awaited hope and this milestone underscores the collective efforts of multiple stakeholders who never stopped pushing for better therapeutic options for IPF.

KaminskiMed @kaminskimed.bsky.social · 26d

Yesterday, the U.S. FDA approved Jascayd (nerandomilast) to treat IPF. This is the first IPF new therapy approved in more than a decade.
Congratulations to all our patients & yes, better drugs are on the way!!
Great day for the #CureIPF community!!
#ScienceMatters
www.fda.gov/drugs/news-e...

FDA approves drug to treat idiopathic pulmonary fibrosis

First new treatment in more than a decade for rare lung condition

www.fda.gov

1

Reposted by Teja Kulkarni

KaminskiMed @kaminskimed.bsky.social · 26d

Yesterday, the U.S. FDA approved Jascayd (nerandomilast) to treat IPF. This is the first IPF new therapy approved in more than a decade.
Congratulations to all our patients & yes, better drugs are on the way!!
Great day for the #CureIPF community!!
#ScienceMatters
www.fda.gov/drugs/news-e...

FDA approves drug to treat idiopathic pulmonary fibrosis

First new treatment in more than a decade for rare lung condition

www.fda.gov

2 6

Reposted by Teja Kulkarni

Kerri Johannson MD MPH @kerrijohannson.bsky.social · Sep 2

TETON-2 phase 2 RCT of nebulized treprostinil for IPF 🫁

Positive trial 🗞️
Change in FVC at 52 weeks difference of 95.6mL (!), and 2* endpoints like K-BILD

@ipfdoc.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social

www.theglobeandmail.com/investing/ma...

1 4 7

Reposted by Teja Kulkarni

Kerri Johannson MD MPH @kerrijohannson.bsky.social · May 12

Heading to #ATS2025 🫁?
Wondering about the Clinical Problems assembly content?
📻 Check out this podcast where we break it down for you 👇😁

@ats-clinicalprobs.bsky.social
@atsearlycareer.bsky.social

ATS Clinical Problems Assembly @ats-clinicalprobs.bsky.social · May 12

#ATS2025 starts THIS WEEK! Prepare with our 🌟NEW PODCAST🌟 the CP Assembly's roadmap 🗺️ to #ATS2025! Join host Dr. @kerrijohannson.bsky.social as she breaks down must-see sessions at #ATS2025 with Drs. Kerri Aaronson, Justin Oldham, and Surya Bhatt
youtu.be/5iVM9_yDXsE

Clinical Problems Assembly Roadmap to ATS 2025

Drs. Kerri Aronson, Surya Bhatt, and Justin Oldham join Dr. Kerri Johannson to give CP Assembly members a rundown of to our sessions ATS 2025 conference in S...

youtu.be

4 6

Teja Kulkarni @tkulkarni.bsky.social · May 9

Amplification of patients voices is key to personalized care. Excited about our recent study highlighting the disease burden and critical gaps as we move towards patient focused management for individuals living with IPF #curePF bmcpulmmed.biomedcentral.com/articles/10....

Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study - BMC Pulmonary Medicine

Background The antifibrotic therapies, pirfenidone and nintedanib, have been approved since 2014 for idiopathic pulmonary fibrosis (IPF), but in the United States only a quarter of people living with ...

bmcpulmmed.biomedcentral.com

2 4

Teja Kulkarni @tkulkarni.bsky.social · Apr 14

Had the same question when I saw this paper- typically co-manage SSc patients with our rheumatology colleagues and ILD team are predominant prescribers for Nintedanib.

1

Reposted by Teja Kulkarni

John Kim @jskim8223.bsky.social · Mar 22

Informative piece in @naturerevdrugdisc.bsky.social on cross-organ fibrosis and informing drug development. @ipfdoc.bsky.social @gilliangoobie.bsky.social @kerrijohannson.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @drdayjee.bsky.social
www.nature.com/articles/s41...

Fibrosis: cross-organ biology and pathways to development of innovative drugs - Nature Reviews Drug Discovery

Fibrosis is a key characteristic of a range of chronic diseases that has been challenging to target with drugs. This Review highlights core pathways active in fibrotic conditions across organs, as wel...

www.nature.com

4 13

Reposted by Teja Kulkarni

KaminskiMed @kaminskimed.bsky.social · Mar 3

Exactly. Think about it - what if this drug improves FVC - what would the patients’ risk tolerance be?

1 2

Teja Kulkarni @tkulkarni.bsky.social · Mar 3

Hope so! Especially since there seems to be an efficacy signal.

1 1

Reposted by Teja Kulkarni

ATS Clinical Problems Assembly @ats-clinicalprobs.bsky.social · Jan 16

The ATS CP apprenticeship program is a great way to get involved with the assembly!

Get more info and apply here:
tinyurl.com/439v6xam

Make sure to select the clinical problems assembly and apply before January 24!⏰

#pulmsky #medsky

American Thoracic Society | ATS Apprenticeship Program

The American Thoracic Society is the world's leading medical society dedicated to accelerating the advancement of global respiratory health through…

tinyurl.com

4 4

Reposted by Teja Kulkarni

Kerri Johannson MD MPH @kerrijohannson.bsky.social · Jan 4

🌟 Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease 🌟

Just out in @atsblueeditor.bsky.social 🫁

www.atsjournals.org/doi/abs/10.1...

State of the Art:
-Epidemiology
-Mechanisms of Injury
-Implications - clinical & policy
-Future directions

Screenshot of the article title and authors

1 6 21

Teja Kulkarni @tkulkarni.bsky.social · Jan 3

Happy New Year!

1

Teja Kulkarni @tkulkarni.bsky.social · Jan 3

Please add me too! #CurePF

1 1

Reposted by Teja Kulkarni

Kerri Johannson MD MPH @kerrijohannson.bsky.social · Dec 21

Now can we use CA-125 as a theragnostic biomarker of treatment response in patients with IPF? Why wouldn't we?

@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social

pmc.ncbi.nlm.nih.gov/articles/pmi...

screenshot of study title. Effects of nintedanib on biomarkers in IPF in ERJ Open.

2 6 10

Teja Kulkarni @tkulkarni.bsky.social · Dec 5

An excellent 🧵on potential application of Mendelian randomization towards target identification and therapeutic development #cureIPF #REMAP-ILD

Gísli @ipfdoc.bsky.social · Dec 5

Using Mendelian Randomisation to identify causal associations in #IPF a 🧵

1 3

Reposted by Teja Kulkarni

Chris Carroll, MD @chriscarrollmd.com · Dec 3

There’s still time to submit session ideas for #CHEST2025! Don't miss your chance to speak! Need help? Just ask me! info.chestnet.org/chest-call-f...

2 1 5

Teja Kulkarni @tkulkarni.bsky.social · Nov 27

👆I feel like if it is used responsibly to aid with language (and not the underlying science), there might be precedence to allow it- wouldn’t it be easy to implement this though.

3

Teja Kulkarni @tkulkarni.bsky.social · Nov 26

🙋‍♀️

1

Teja Kulkarni @tkulkarni.bsky.social · Nov 23

👋 I'm a pulmonary critical care physician and ILD specialist at UAB. Within ATS, I'm active in the Clinical Problems Assembly!

1 5

Teja Kulkarni @tkulkarni.bsky.social · Nov 21

Among other factors, this real-world study underscores the importance of addressing mental health in patients with IPF #curePF

American Thoracic Society (ATS) @atscommunity.bsky.social · Nov 21

In idiopathic pulmonary fibrosis (IPF), lack of persistence in following antifibrotic therapy was linked to patient variables that included depression, lower DLCO, higher all-cause mortality, and worse transplant-free survival: Annals of the ATS.

www.pulmonologyadvisor.com/news/ipf-ant...

IPF Antifibrotic Therapy Discontinuation Linked to Depression, Lower DLCO

In IPF, antifibrotic therapy discontinuation was linked to patient variables that included depression, lower DLCO, and higher all-cause mortality.

www.pulmonologyadvisor.com

1 1

Reposted by Teja Kulkarni

Rabin @rabinperspective.bsky.social · Nov 21

Continued awareness and identification of IPF needs to continue.

American Thoracic Society (ATS) @atscommunity.bsky.social · Nov 21

In idiopathic pulmonary fibrosis (IPF), lack of persistence in following antifibrotic therapy was linked to patient variables that included depression, lower DLCO, higher all-cause mortality, and worse transplant-free survival: Annals of the ATS.

www.pulmonologyadvisor.com/news/ipf-ant...

IPF Antifibrotic Therapy Discontinuation Linked to Depression, Lower DLCO

In IPF, antifibrotic therapy discontinuation was linked to patient variables that included depression, lower DLCO, and higher all-cause mortality.

www.pulmonologyadvisor.com

1 2

Teja Kulkarni @tkulkarni.bsky.social · Nov 20

🙋‍♀️

Reposted by Teja Kulkarni

Gísli @ipfdoc.bsky.social · Nov 19

So excited to hear what @kerrijohannson.bsky.social has to tell us about the impact of our environment on the development of pulmonary fibrosis! The whole lecture will be available on-line via the MTW website: www.imperial.ac.uk/mtw-centre-f...

2 2 6

Reposted by Teja Kulkarni

KaminskiMed @kaminskimed.bsky.social · Nov 16

Really cool! our “Single-Cell Analysis Reveals Novel Immune Perturbations in Fibrotic Hypersensitivity Pneumonitis” made it to cover of the American Journal of Respiratory & Critical Care Medicine. Kudos to soon to be #DoubleDoc Amy Zhao & crew!! #BestStudents www.atsjournals.org/doi/full/10....

1 5 25